<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02727387</url>
  </required_header>
  <id_info>
    <org_study_id>ISG/AIEOP EW-2</org_study_id>
    <nct_id>NCT02727387</nct_id>
  </id_info>
  <brief_title>Protocol for the Treatment of Metastatic Ewing Sarcoma</brief_title>
  <acronym>EW-2</acronym>
  <official_title>Study With High Doses of Chemotherapy, Radiotherapy and Consolidation Therapy With Ciclofosfamide and Anticyclooxygenase 2, for the Metastatic Ewing Sarcoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Italian Sarcoma Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Italian Sarcoma Group</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study for the treatment of metastatic Ewing sarcoma with high doses chemotherapy,
      radiotherapy and maintenance therapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study for the treatment of Ewing metastatic sarcoma with and induction phase with Vincristine
      (VIN), Adriamycin (ADM), Ciclofosfamide(CYC), Ifosfamide(IFO), Etoposide(ETO) and
      radiotherapy (RT)followed by a consolidation phase with Busulfan and Melfalan (BUMEL) and
      Peripheral Blood Stem Cells Transplantation (PBSCT) and a subsequent maintenance phase with
      Ciclofosfamide and Celecoxib for High Risk (HR) patients.

      Very High Risk (VHR) patients will receive a prior frontline therapy with Temozolomide and
      Irinotecan (TEMIRI), while patient with lung metastasis only will undergo to total lung
      irradiation after PBSCT
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2009</start_date>
  <completion_date type="Anticipated">May 2020</completion_date>
  <primary_completion_date type="Anticipated">May 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>Expected average 3 year</time_frame>
    <description>Evaluation of the OS in patients treated according to the protocol</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Event Free Survival (DFS)</measure>
    <time_frame>Expected average 1 year</time_frame>
    <description>Evaluation of the time in which the patient do not experience any progression, relapse of toxicity event when treated according to the protocol</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety - Incidence and grade of treatment-emergent Adverse Events</measure>
    <time_frame>every 21 days up to 1 year</time_frame>
    <description>Incidence and grade of treatment-emergent Adverse Events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>every 3 weeks for the first 6 months and 3 monthly up to 1 year</time_frame>
    <description>Evaluation of patient's quality of life: data will be collected by using specific oncologic Quality of Life instruments</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Ewing's Sarcoma (ES)</condition>
  <arm_group>
    <arm_group_label>TEMIRI+VIN+ADM+IFO+ CYC+ETO+BUMEL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2cycles of Temozolomide(500 mg/m2)+Irinotecan(250 mg/m2) and 2cycles of Vincristine(1.4mg/m2)+ Adriamycin(90mg/m2)+Ifosfamide (9gr/m2) alternes with 2 cycles of Ciclofosfamide(4g/m2)+Etoposide (600mg/m2) followed by radiotherapy (42-54 Gy) and 2cycles of Ifosfamide (9gr/m2) + Etoposide(300mg/m2) alternes with to 2cycles of Vincristine (1.4mg/m2)+ Adriamycin (80mg/m2)+ Ciclofosfamide(1.2g/m2) and Busulfan(0.8-1.2 mg/Kg)+Melfalan(140 mg/m2)+PBSCT and 6 months with Celecoxib (500mg/m2/die for&lt;14 years old ,800 mg/die for&gt;14 years old) Ciclofosfamide (oral therapy 35mg/m2/die for&lt;14 years old, 50 mg/m2 for&gt;14 years old)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TEMIRI</intervention_name>
    <description>Window therapy frontline for VHR patients</description>
    <arm_group_label>TEMIRI+VIN+ADM+IFO+ CYC+ETO+BUMEL</arm_group_label>
    <other_name>Temozolomide + Irinotecan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ADM</intervention_name>
    <description>Drug used in the Induction phase in association with Vincristine, Ifosfamide, cyclophosphamide and Etoposide</description>
    <arm_group_label>TEMIRI+VIN+ADM+IFO+ CYC+ETO+BUMEL</arm_group_label>
    <other_name>Adriamycin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IFO</intervention_name>
    <description>Drug used in the Induction phase in association with Vincristine, Adriamycin, cyclophosphamide and Etoposide</description>
    <arm_group_label>TEMIRI+VIN+ADM+IFO+ CYC+ETO+BUMEL</arm_group_label>
    <other_name>Ifosfamide</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CYC</intervention_name>
    <description>Drug used in the Induction phase in association with Vincristine, Ifosfamide, Adriamycin and Etoposide</description>
    <arm_group_label>TEMIRI+VIN+ADM+IFO+ CYC+ETO+BUMEL</arm_group_label>
    <other_name>Cyclophosphamide</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ETO</intervention_name>
    <description>Drug used in the Induction phase in association with Vincristine, Ifosfamide, cyclophosphamide and Adriamycin</description>
    <arm_group_label>TEMIRI+VIN+ADM+IFO+ CYC+ETO+BUMEL</arm_group_label>
    <other_name>Etoposide</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BUMEL</intervention_name>
    <description>Consolidation phase</description>
    <arm_group_label>TEMIRI+VIN+ADM+IFO+ CYC+ETO+BUMEL</arm_group_label>
    <other_name>busulfan + melphalan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VIN</intervention_name>
    <description>Drug used in the Induction phase in association with cyclophosphamide , Ifosfamide, Adriamycin and Etoposide</description>
    <arm_group_label>TEMIRI+VIN+ADM+IFO+ CYC+ETO+BUMEL</arm_group_label>
    <other_name>Vincristine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically proven Ewing's sarcoma

          -  Age â‰¤ 40 years

          -  No previous treatment

          -  Multiple skeletal metastasis or bone marrow infiltration , with/without lung/pleural
             metastasis

          -  Signed Informed Consent

        Exclusion Criteria:

          -  Localized Ewing's sarcoma

          -  Any contraindications to the study treatment

          -  Female patients who not accept to use an effective birth control method.

          -  Pregnant or breast-feeding patients
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Centro di Riferimento Oncologico - Unit of Medical Oncology</name>
      <address>
        <city>Aviano</city>
        <state>Pordenone</state>
        <zip>33081</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Maurizio Mascarin, MD</last_name>
      <phone>+390434659</phone>
      <phone_ext>536</phone_ext>
      <email>mascarin@cro.it</email>
    </contact>
    <investigator>
      <last_name>Maurizio Mascarin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>I.R.C.C. - Unit of Medical Oncology</name>
      <address>
        <city>Candiolo</city>
        <state>Torino</state>
        <zip>10060</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Massimo Aglietta, MD</last_name>
      <phone>+39.011.9933</phone>
      <phone_ext>628</phone_ext>
      <email>massimo.aglietta@ircc.it</email>
    </contact>
    <investigator>
      <last_name>Massimo Aglietta, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Giovanni Grignani, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Istituto Ortopedico Rizzoli - Unit of Chemotherapy of Muscoloskeletal Tumors</name>
      <address>
        <city>Bologna</city>
        <zip>40136</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stefano Ferrari, MD</last_name>
      <phone>+390516366199</phone>
      <phone_ext>199</phone_ext>
      <email>stefano.ferrari@ior.it</email>
    </contact>
    <investigator>
      <last_name>Stefano Ferrari, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Servizio di Oncoematologi Pediatrica Ospedale microcitemico ASL 8</name>
      <address>
        <city>Cagliari</city>
        <zip>Rosamaria</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rosamaria Mura, MD</last_name>
      <phone>+39070504208</phone>
    </contact>
    <investigator>
      <last_name>Rosamaria Mura, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>A.O. Universitaria Meyer</name>
      <address>
        <city>Firenze</city>
        <zip>50139</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Angela Tamburini, MD</last_name>
      <phone>+3905556</phone>
      <phone_ext>621</phone_ext>
      <email>a.tamburini@meyer.it</email>
    </contact>
    <investigator>
      <last_name>Angela Tamburini, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Istituto Giannina Gaslini</name>
      <address>
        <city>Genova</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carla Manzitti, MD</last_name>
      <phone>0105636 2431</phone>
    </contact>
    <investigator>
      <last_name>Carla Manzitti, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fondazione IRCCS INT Milano</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rossella Bertulli, MD</last_name>
      <phone>+390223903</phone>
      <phone_ext>287</phone_ext>
      <email>rossella.bertulli@istitutotumori.mi.it</email>
    </contact>
    <investigator>
      <last_name>Rossella Bertulli, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fondazione IRCCS INT Milano</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roberto Luksch, MD</last_name>
      <phone>+390223903</phone>
    </contact>
    <investigator>
      <last_name>Roberto Luksch, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale Pediatrico Bambin Gesu'</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Raffaele Cozza, MD</last_name>
      <phone>+39065266919</phone>
    </contact>
    <investigator>
      <last_name>Raffaele Cozza, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale Infantile Regina Margherita - Unit of Paediatric Oncoematology</name>
      <address>
        <city>Torino</city>
        <zip>10126</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Franca Fagioli, MD</last_name>
      <phone>+39.011.3135</phone>
      <phone_ext>230</phone_ext>
      <email>franca.fagioli@unito.it</email>
    </contact>
    <investigator>
      <last_name>Franca Fagioli, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <link>
    <url>http://www.italiansarcomagroup.org/wp-content/uploads/2014/04/EW2.pdf</url>
    <description>Study synopsis</description>
  </link>
  <reference>
    <citation>Picci P, BÃ¶hling T, Bacci G, Ferrari S, Sangiorgi L, Mercuri M, Ruggieri P, Manfrini M, Ferraro A, Casadei R, Benassi MS, Mancini AF, Rosito P, Cazzola A, Barbieri E, Tienghi A, Brach del Prever A, Comandone A, Bacchini P, Bertoni F. Chemotherapy-induced tumor necrosis as a prognostic factor in localized Ewing's sarcoma of the extremities. J Clin Oncol. 1997 Apr;15(4):1553-9.</citation>
    <PMID>9193352</PMID>
  </reference>
  <reference>
    <citation>Gardner SL, Carreras J, Boudreau C, Camitta BM, Adams RH, Chen AR, Davies SM, Edwards JR, Grovas AC, Hale GA, Lazarus HM, Arora M, Stiff PJ, Eapen M. Myeloablative therapy with autologous stem cell rescue for patients with Ewing sarcoma. Bone Marrow Transplant. 2008 May;41(10):867-72. doi: 10.1038/bmt.2008.2. Epub 2008 Feb 4.</citation>
    <PMID>18246113</PMID>
  </reference>
  <reference>
    <citation>Paulussen M, Ahrens S, Burdach S, Craft A, Dockhorn-Dworniczak B, Dunst J, FrÃ¶hlich B, Winkelmann W, Zoubek A, JÃ¼rgens H. Primary metastatic (stage IV) Ewing tumor: survival analysis of 171 patients from the EICESS studies. European Intergroup Cooperative Ewing Sarcoma Studies. Ann Oncol. 1998 Mar;9(3):275-81.</citation>
    <PMID>9602261</PMID>
  </reference>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 23, 2016</study_first_submitted>
  <study_first_submitted_qc>April 1, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 4, 2016</study_first_posted>
  <last_update_submitted>April 9, 2018</last_update_submitted>
  <last_update_submitted_qc>April 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 11, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarcoma</mesh_term>
    <mesh_term>Sarcoma, Ewing</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Busulfan</mesh_term>
    <mesh_term>Temozolomide</mesh_term>
    <mesh_term>Ifosfamide</mesh_term>
    <mesh_term>Isophosphamide mustard</mesh_term>
    <mesh_term>Irinotecan</mesh_term>
    <mesh_term>Etoposide phosphate</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Vincristine</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

